Thymosin Alpha-1: What People Actually Pay (Plus Real-World Results)
At a glance
- US approval status / Not FDA-approved; four orphan designations, which are not approvals [1]
- Cochrane review, hepatitis B / Very low certainty; reviewers not sure it helps [2]
- Approved as a medicine in / Italy, India and Hong Kong, as Zadaxin 1.6 mg injection [1]
- Compounding advisory vote / 4 yes, 17 no, December 2024 [3]
- WADA 2026 Prohibited List / Does not name thymosin alpha-1 [4]
- Serum half-life / approximately 2 hours [5]
How much does thymosin alpha-1 cost in the US?
There is no verifiable published US price. FDA has no approved US application for thymosin alpha-1 (thymalfasin) [1]. Zadaxin is the finished 1.6 mg injection sold outside the United States and is not interchangeable with bulk thymosin alpha-1 powder [1]. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [6]. The FDA materials do not address whether health plans pay for thymosin alpha-1.
What FDA has said about compounded thymosin alpha-1
Thymosin alpha-1 sits in the 'nominated but withdrawn' table on FDA's page about bulk substances that may present significant safety risks; it had been in the significant-risk category until the nominators withdrew [7]. FDA's posted concerns remain: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information the agency called inadequate to understand the extent of any safety issues [7].
It is in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), and in category 3, 'nominated without adequate support', on the list for outsourcing facilities (updated March 21, 2025) [8][9]. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [3]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [10].
What the trials show
The 2026 Cochrane review pooled 10 randomized trials in 1,349 adults with chronic hepatitis B, published 1991 to 2018. Thymosin alpha-1, alone or with interferon, lamivudine, entecavir or tenofovir, was compared with placebo, no treatment or the same co-treatment. It found possibly lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people), but the certainty was very low. It found little to no effect on quality of life or liver histology, and the effect on hepatitis B-related illness was very uncertain [2].
One trial in that field was Lim and colleagues in 2006: a double-blind, placebo-controlled trial in 98 adults with HBeAg-positive chronic hepatitis B, given 24 weeks of lymphoblastoid interferon with thymosin alpha-1 (n=48) or with placebo (n=50). HBeAg loss at 72 weeks was 45.8% versus 28.0%, a difference of 17.8% (95% CI -1.2 to 35.3; P=0.067) that did not reach statistical significance [11]. An earlier pilot of 12 people gave thymosin fraction 5 or thymosin alpha-1 to 7 and placebo to 5; HBV DNA cleared in 6 of 7 treated versus 1 of 5 on placebo (P<0.04). It was very small and reported no significant side effects [12].
What the safety record shows
FDA's search of its adverse-event database on April 22, 2024 returned zero reports for thymosin alpha-1. Authors tied to the manufacturer report more than 4,400 trial participants and more than 17 million post-marketing doses of Zadaxin, with adverse experiences described as 'infrequent and mild' [1]. These are company-linked figures about use, not measures of how well it works or how often side effects occur. In the Cochrane review, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (RR 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (very low-certainty evidence) [2].
What dose is documented, and what the label says
No US-approved dose exists [1]. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first influenza vaccination, repeated from week 8 to week 12 at the second vaccination. The label says the product is not for children and is contraindicated in pregnancy and breastfeeding, and it calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1]. After subcutaneous injection, thymosin alpha-1 reaches peak serum concentrations within about two hours and has a serum half-life of approximately two hours [5].
Frequently asked questions
Does thymosin alpha-1 work for chronic hepatitis B?
Is thymosin alpha-1 FDA-approved?
What did the 2006 placebo-controlled trial of thymosin alpha-1 find?
Is thymosin alpha-1 banned in sport?
How long does thymosin alpha-1 stay in the body?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Compounding and the FDA: Questions and Answers | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
- Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.